ThursdayDec 23, 2021 9:30 am

FDA Releases Clinical Trial Guidelines Taking into Account CNS Metastases

The Food and Drug Administration recently released new guidance informing sponsors of clinical trials on recommendations to trial designs for systemic oncologic treatments in individuals with central nervous system metastases. According to the new guidelines, researchers must consider leptomeningeal disease, end points, central nervous system assessment, prior therapies and patient population when designing clinical trials. The assessment of tumors is best done through magnetic resonance imaging (“MRI”) with gadolinium contrast. The agency recommends that the involvement of the central nervous system (“CNS”) not be assessed separately from other metastatic illnesses present in other parts of a patient’s body. It adds…

Continue Reading

WednesdayDec 22, 2021 12:38 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Complete Initial Shipment of sugarBEAT(R) Devices to UK Licensee

Nemaura Medical announced the successful completion of its initial shipment of sugarBEAT(R) continuous glucose monitor devices to its UK licensee The initial shipment, which comprised 5,000 CGM devices and 200,000 sensors, is expected to result in follow-on monthly orders of up to 2 million sensors and 15,000 CGM devices over the next two years Following the launch of the sugarBeat(R), Nemaura Medical have released the MiBoKo application, designed to help individuals track their metabolic health scores Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, revealed…

Continue Reading

WednesdayDec 22, 2021 9:30 am

Study Finds That Mental Health Services Shortage is Frustrating Parents

A recently conducted survey has found that only 50% of parents who tried acquiring mental health services for their children during the coronavirus pandemic were successful in their attempts. The survey was carried out in September 2021 by DotCom Therapy, a pediatric teletherapy provider. The objective of the survey was to measure the effect of the pandemic on mental health in children, as well as how children were impacted by going back to physical classes after a year of online learning and the coronavirus lockdown. The survey collected responses from more than 1,000 guardians and parents in the United States…

Continue Reading

TuesdayDec 21, 2021 2:00 pm

Addiction Psychiatrist Offers Coping Tips Against Drinking During Holidays

The holidays, family gatherings and holiday celebrations are often filled with fun, good food and alcohol on occasion. Individuals with alcohol addiction may be vulnerable during this time, especially if they’re being invited to places with booze. Ideally, not having alcohol around would be best, but that isn’t always possible. Addiction psychiatrist Dr. Lauren Grawert gives a few tips on how to handle situations like this. Grawert states that it’s good to have a preplanned response ready when you, as a recovering alcohol addict, are offered an alcoholic drink. She highlights that it should be something you’re comfortable saying. Here…

Continue Reading

MondayDec 20, 2021 12:13 pm

RYAH Group Inc. (CSE: RYAH) Releases Medical Cannabis Report on Cancer and Adverse Cancer Treatment Effects

RYAH recently released report highlighting medical cannabis treatment for cancer and adverse effects of cancer treatment Data from 80,000 sessions logged between January 1, 2018 and November 15, 2021 tracked conditions including anxiety, cachexia, fatigue, pain, nausea, and stress 62% of patients reported a moderate experience using cannabis to treat cancer-related conditions RYAH supports cancer research and treatment with IoT product ecosystem comprised of volume-control devices, medicine-carrying components, mobile applications RYAH Group (CSE: RYAH), the leader in volume-control technology for plant-based medicine, recently released a medical cannabis report on cancer and the adverse effects of cancer treatment (https://ibn.fm/Es52b). Data from…

Continue Reading

MondayDec 20, 2021 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment

Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space  The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022 Mydecine has put systems and infrastructure in place to bank on the growing PTSD treatment, smoking cessation, and the health and wellness apps market, in its drive to increase value for its shareholders There has been a huge misunderstanding of the psychedelic space and the potential that this industry has, specifically regarding the treatment of Post-Traumatic Stress Disorder (“PTSD”) and smoking cessation.…

Continue Reading

MondayDec 20, 2021 9:38 am

Understanding Prostate Cancer’s Early Warning Signs

Estimates show that nearly 200,000 Americans are diagnosed with prostate cancer annually, making it one of the most commonly diagnosed cancers after breast and lung cancer. The survival rate for this particular cancer is high, especially if diagnosed in its early stages. Figures show that when this cancer is diagnosed before it metastasizes, roughly 97% of individuals live at least five years after diagnosis. However, most individuals with prostate cancer don’t display any symptoms or signs, especially when the disease is still in its early stages. This is why it’s important to know some of the signs of prostate cancer,…

Continue Reading

FridayDec 17, 2021 2:00 pm

Study Finds CBD Cigarettes Decrease Use of Antipsychotic Medications

CBD cigarettes are cigarettes manufactured from hemp instead of tobacco. The cigarettes contain CBD and a small amount of THC. CBD is a nonpsychoactive compound found in cannabis while THC is the psychoactive compound that induces a high. Data from a new trial has found that the use of CBD cigarettes is linked to a decrease in patients’ use of antipsychotic drugs. The cigarettes’ effects usually last two to three hours and take between a few seconds and some minutes to set in. This mode of consumption makes it the fastest way to feel CBD’s effects. The placebo-controlled trial was…

Continue Reading

ThursdayDec 16, 2021 12:00 pm

Yale Studies Could Lead to Improved Treatment of Cancer

Two new studies led by researchers from Yale have discovered new information about the ALK receptor (anaplastic lymphoma kinase molecule) and the role it plays in cancer formation. The studies have made progress in determining ALK’s structure status as a receptor protein. Their findings were published in “Nature.” The codirector of the Cancer Biology Institute, Joseph Schlessinger, is a senior author of one of the studies. Yale School of Medicine assistant professor of pharmacology Daryl Klein is the senior author of the second study. A postdoctoral associate in Klein’s laboratory, Tongqing Li, stated that ALK was one of the receptor…

Continue Reading

WednesdayDec 15, 2021 11:06 am

Drug Addiction: The US Searches for Novel Ways to Prevent Overdoses

Opioids are a class of drugs made from the opium poppy plant. These drugs work in the brain to produce various effects, including pain relief. Opioids are usually given as prescription medications to treat moderate to severe pain. However, long-term use of the drugs increases an individual’s dependence and tolerance, which results in higher and more frequent doses and sometimes addiction. In 2019, almost 50,000 individuals in the United States died from opioid-related overdoses. This number has steadily increased since then, with the most recent figures showing that 100,000 people have died because of overdoses associated with fentanyl in the…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050